Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-03-14
2010-06-22
Juedes, Amy E (Department: 1644)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S278100
Reexamination Certificate
active
07741271
ABSTRACT:
The invention relates to methods of modulating immune responses in a subject, such as by administering to the subject agents which modulate tim-1, tim-2 or tim-4 activity, or which modulate the physical interaction between tim-1 and tim-4 or between tim-2 and a tim-2 ligand. Immune responses include, but are not limited to, autoimmune disorders, transplantation tolerance, and Th1 and Th2-mediated responses and disorders. The invention also relates to novel assays for identifying agents which modulate the physical interaction between tim-1 and tim-4. In addition, the invention relates to novel soluble tim-4 polypeptides and to nucleic acids which encode them.
REFERENCES:
patent: 6027916 (2000-02-01), Ni et al.
patent: 6066322 (2000-05-01), Levinson
patent: 6066498 (2000-05-01), Levinson
patent: 6084083 (2000-07-01), Levinson
patent: 6156887 (2000-12-01), Levinson
patent: 6190909 (2001-02-01), Levinson et al.
patent: 6204371 (2001-03-01), Levinson
patent: 6288218 (2001-09-01), Levinson
patent: 6414117 (2002-07-01), Levinson
patent: 6455685 (2002-09-01), Levinson
patent: 6468768 (2002-10-01), Ni et al.
patent: 6562343 (2003-05-01), Levinson
patent: 2003/0069196 (2003-04-01), Levinson et al.
patent: 2003/0124114 (2003-07-01), McIntire et al.
patent: 2004/0005322 (2004-01-01), Kuchroo et al.
patent: 2005/0276756 (2005-12-01), Hoo et al.
patent: WO-98/15624 (1997-10-01), None
patent: WO 99/35158 (1999-07-01), None
patent: WO 01/57188 (2001-08-01), None
patent: WO-0155304 (2001-09-01), None
patent: WO-02081517 (2002-10-01), None
patent: WO-03/002722 (2003-01-01), None
patent: WO-03/063792 (2003-08-01), None
patent: WO 03/080673 (2003-10-01), None
patent: WO 2004/060041 (2004-07-01), None
patent: WO 2005/027854 (2005-03-01), None
Loza et al., 2005, Clin. Exp. Allergy, vol. 35: 8-17 de Souza et al., 2005, PNAS, vol. 102: 17113-17118.
Meyers et al., 2005, Trends in Mol. Med. vol. 11: 362-369.
Meyers et al., 2005, Nat. Immunol. vol. 6: 455-464.
Burgess et al., 1990, J. Cell. Biol. vol. 111: 2129-2138.
Mikayama, 1993, PNAS, vol. 90: 10056-60. Whisstock et al., 2003, Quart. Rev. Biophys. vol. 36: 307-340.
Lazar et al., 1988, Mol. Cell. Biol. vol. 8: 1247-1252. Encinas et al., 2005, J. Allergy Clin. Immunol. vol. 116: 1343-9.
Santiago et al., 2007, Immunity, vol. 26: 299-310. Singh, 2003, Clin. Immunol. vol. 108: 73-79.
Theofilopoulos et al. Arthritis Res. vol. 3: 136-141.
No Author-Sequence Curated my NCBI staff: “Galectin 9 short isoform (human)”; Genbank Accession No. NP—002299; (First published online on Mar. 24, 1999).
No Author-Sequence Curated my NCBI staff: Genbank Accession No. NP—033665, galection 9 long isoform (human). (First published online on Jan. 28, 2000).
No Author-Sequence Curated my NCBI staff: Genbank Accession No. NP—034838, lectin, galactose binding, soluble 9 (mouse). (First published online on Jan. 26, 2000 ).
No Author-Sequence Curated my NCBI staff: Genbank Accession No. NP—036338; hepatitis A virus cellular receptor 1 [Homo sapiens] (First published online on Feb. 7, 2000).
No Author-Sequence Curated my NCBI staff: Genbank Accession No. NM—012206; Homo sapiens hepatitis A virus cellular receptor 1 (HAVCR1), mRNA. (First published online on Feb. 7, 2000).
No Author-Sequence Curated my NCBI staff: Genbank Accession No. NP—599009; hepatitis A virus cellular receptor 1 [Mus musculus]. (First published online on Feb. 7, 2000).
No Author-Sequence Curated my NCBI staff. Genbank Accession No. NM—134248; Mus musculus hepatitis A virus cellular receptor 1 (Havcr1), mRNA (First published online on Mar. 18, 2002).
No Author-Sequence Curated my NCBI staff: Genbank Accession No. NP—599010; T-cell immunoglobulin and mucin domain containing 2 [Mus musculus]. (First published online on Mar. 18, 2002).
No Author-Sequence Curated my NCBI staff: Genbank Accession No. NM—134249; Mus musculus T-cell immunoglobulin and mucin domain containing 2(Timd2), mRNA. (First published online on Mar. 18, 2002).
No Author-Sequence Curated my NCBI staff: Genbank Accession No. NP—848874; T-cell immunoglobulin and mucin domain containing 4 [Mus musculus]. (First published online on May 10, 2003).
No Author-Sequence Curated my NCBI staff: Genbank Accession No. NM—178759; Mus musculus T-cell immunoglobulin and mucin domain containing 4 (Timd4), mRNA (First published online on May 10, 2003).
No Author-Sequence Curated my NCBI staff: Genbank Accession No. NP—071762; semaphorin B [Homo sapiens]. (First published online on Dec. 12, 2000).
Bailly et al. Shedding of kidney injury molecule-1, a putative adhesion protein involved in renal regeneration.J Biol Chem. 2002;277(42):39739-48.
Chae Sc. et al. The exon 4 variations of Tim-1 gene are associated with rheumatoid arthritis in a Korean population.Biochem Biophys Res Commun. 2004;315(4):971-5.
U.S. Appl. No. 10/958,169, filed Oct. 4, 2004, Kuchroo et al.
Chae Sc. et al. The association of the exon 4 variations of Tim-1 gene with allergic diseases in a Korean population.Biochem Biophys Res Commun. 2003;312(2):346-50.
Chae Sc. et al. Molecular variations in the promoter and coding regions of human Tim-1 gene and their association in Koreans with asthma.Hum Immunol. 2003; 64(12):1177-82.
Feigelstock D. et al. The human homolog of HAVcr-1 codes for a hepatitis A virus cellular receptor.J Virol. 1998;72(8):6621-8.
Ichimura T. et al. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury.J Biol Chem. 1998;273(7):4135-42.
Kaplan, G. et al. Identification of a surface glycoprotein on African green monkey kidney cells as a receptor for hepatitis A virus. EMBO J. 15, 4282-4296 (1996).
Khademi M. et al. T Cell Ig- and mucin-domain-containing molecule-3 (TIM-3) and TIM-1 molecules are differentially expressed on human Th1 and Th2 cells and in cerebrospinal fluid-derived mononuclear cells in multiple sclerosis.J. Immunol. 2004;172(11):7169-76.
Kikutani H. et al. Semaphorins in interactions between T cells and antigen-presenting cells.Nat Rev Immunol. 2003;3(2):159-67.
Kuchroo, V. et al. The TIM gene family: emerging roles in immunity and disease. Nat Rev Immunol 3, 454-462 (2003).
Kumanogoh A. et al. Immune semaphorins: a new area of semaphorin research.J Cell Sci. 2003;116(Pt 17):3463-70.
Kumanogoh A. et al. Class IV semaphorin Sema4A enhances T-cell activation and interacts with Tim-2.Nature. 2002; 419(6907):629-33.
McIntire JJ. et al. TIM-1, a novel allergy and asthma susceptibility gene. Springer Semin Immunopathol. 2004;25(3-4):335-48. Epub Oct. 24, 2003.
McIntire, J. et al. Identification of Tapr (an airway hyperreactivity regulatory locus) and the linked Tim gene family. Nat Immunol 2, 1109-1116 (2001).
Monney L. et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease.Nature. 2002;415(6871):536-41.
Noguchi E. et al. Insertion/deletion coding polymorphisms in hHAVcr-1 are not associated with atopic asthma in the Japanese population.Genes Immun. 2003;4(2):170-3.
Rabinovich GA. et al. Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response?Trends Immunol23:313-320; 2002.
Rabinovich GA. et al. Role of galectins in inflammatory and immunomodulatory processesBiochim Biophys Acta1572:274-284, 2002.
Sabatos CA. et al. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance.Nat Immunol4:1102-1110, 2003.
Sanchez-Fueyo, A. et al. The Ig superfamily member Tim-3 inhibits Th1-mediated auto- and allo-immune response and promotes immunological tolerance.Nat Immunol4:1093-1101, 2003.
Shakhov AN. et al. Smuckler/TIM4 is a distinct member of TIM family expressed by stromal cells of secondary lymphoid tissues and associated with lymphotoxin signaling.Eur J Immunol. 2004;34(2):494-503.
Silberstein E. et al. Neutralization of hepatitis A virus (HAV) by an immunoadhesin containing the cysteine-rich region of HAV cellular receptor-1
Chakravarti Sumone
Kuchroo Vijay K.
Meyers Jennifer
Strom Terry
Zheng Xin Xiao
Beth Israel Deaconess Medical Center Inc.
Juedes Amy E
Nixon & Peabody LLP
The Brigham and Women's Hospital, Inc.
LandOfFree
Methods of modulating immune responses by modulating tim-1,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of modulating immune responses by modulating tim-1,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of modulating immune responses by modulating tim-1,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4227476